Abstract
Circulating tumour DNA analysis can be used to track tumour burden and analyse cancer genomes non-invasively but the extent to which it represents metastatic heterogeneity is unknown. Here we follow a patient with metastatic ER-positive and HER2-positive breast cancer receiving two lines of targeted therapy over 3 years. We characterize genomic architecture and infer clonal evolution in eight tumour biopsies and nine plasma samples collected over 1,193 days of clinical follow-up using exome and targeted amplicon sequencing. Mutation levels in the plasma samples reflect the clonal hierarchy inferred from sequencing of tumour biopsies. Serial changes in circulating levels of sub-clonal private mutations correlate with different treatment responses between metastatic sites. This comparison of biopsy and plasma samples in a single patient with metastatic breast cancer shows that circulating tumour DNA can allow real-time sampling of multifocal clonal evolution.
Cite
CITATION STYLE
Murtaza, M., Dawson, S. J., Pogrebniak, K., Rueda, O. M., Provenzano, E., Grant, J., … Caldas, C. (2015). Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nature Communications , 6. https://doi.org/10.1038/ncomms9760
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.